Rocket Pharmaceuticals (RCKT) Accumulated Expenses (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Accumulated Expenses data on file, last reported at $5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 25.99% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (down 25.99% YoY), and the FY2025 full-year result was $12.3 million, up 2.93% from the prior year.
• Accumulated Expenses declined to $5.2 million in Q1 2026, from $12.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $12.3 million in Q4 2025 to a low of $405000.0 in Q2 2022.
• A 5-year average of $7.1 million and a median of $7.3 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses tumbled 73.57% in 2022 and surged 1384.69% in 2023, its largest moves.
• Tracing RCKT's Accumulated Expenses over 5 years: stood at $10.0 million in 2022, then dropped by 0.76% to $9.9 million in 2023, then advanced by 20.28% to $11.9 million in 2024, then gained by 2.93% to $12.3 million in 2025, then slumped by 57.42% to $5.2 million in 2026.
• Business Quant data shows RCKT's Accumulated Expenses at $5.2 million in Q1 2026, $12.3 million in Q4 2025, and $11.4 million in Q3 2025.